Dyne Therapeutics prices $200M public offering of 24.2M shares at $8.25/share

Dyne Therapeutics, Inc.

Gross proceeds of $200M; net proceeds ~$187M ($215.2M if underwriters exercise 30-day option for 3.6M additional shares).
Closing expected July 2, 2025; all shares sold by the company, resulting in dilution.
Cash runway extended into Q3 2027 inclusive of June 2025 $100M term loan from Hercules Capital.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.